Dr. Fong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
751 S Bascom Ave
San Jose, CA 95128Phone+1 408-885-5000
Education & Training
- University of WashingtonFellowship, Pediatric Hematology/Oncology, 2007 - 2010
- Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 2004 - 2007
- Pennsylvania State University College of MedicineClass of 2004
Certifications & Licensure
- CA State Medical License 2020 - 2026
- WA State Medical License 2007 - 2019
Clinical Trials
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors Start of enrollment: 2013 Dec 01
- A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) Start of enrollment: 2020 Oct 02
Publications & Presentations
PubMed
- 324 citationsDUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral DystrophyLinda Geng, Zizhen Yao, Lauren Snider, Abraham P. Fong, Jennifer N. Cech
Developmental Cell. 2012-01-17 - 43 citationsConversion of MyoD to a neurogenic factor: binding site specificity determines lineageAbraham P Fong, Zizhen Yao, Jun Wen Zhong, Nathan M. Johnson, Gist H. Farr
Cell Reports. 2015-03-31 - 63 citationsFrontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HLJonathan W. Friedberg, Andres Forero-Torres, Rodolfo Bordoni, Vivian Jean M. Cline, Dipti Patel Donnelly
Blood. 2017-12-28
Grant Support
- K08NIH/NCI2012–2014
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: